Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.0.1340560
European Journal of Endocrinology, Vol 134, Issue 5, 560-562
Copyright © 1996 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chujo, S.
Right arrow Articles by Chihara, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Chujo, S.
Right arrow Articles by Chihara, K.

No correlation of growth hormone receptor gene mutation P561T with body height

Seiko Chujo, Hidesuke Kaji, Yutaka Takahashi, Yasuhiko Okimura, Hiromi Abe and Kazuo Chihara

Chujo S. Kaji H, Takahashi Y. Okimura Y, Abe H, Chihara K. No correlation of growth hormone receptor gene mutation P561T with body height. Eur J Endocrinol 1996;134:560–2. ISSN 0804–4643

Analysis of the growth hormone receptor (GHR) gene in GH insensitivity syndrome revealed various mutations, mainly in the gene encoding the extracellular domain of GHR. On the other hand, the mutation of the gene encoding the cytoplasmic domain of GHR was not found. We have reported, in the cytoplasmic domain of a GHR gene, mutation P561T in a patient with Noonan syndrome who showed a blunted insulin-like growth factor I (IGF-I) response to an acute injection of GH. However, her mother possessing the same mutation had no growth failure. To clarify the significance of the GHR gene mutation P561T, 96 volunteers (41 males aged 21–80 years; 55 females, aged 20–80 years) were tested for the presence of this mutation. By the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method, three of the 41 males and 11 of the 55 females examined revealed heterozygous missense mutation P561T, The body height (cm) was 168 ±5.3 (mean ± SD) in three males with the mutation and 164.1 ± 5.8 in 38 males without the mutation. The difference between them was not statistically significant. The body height in 11 females with the mutation was 152.6 ± 5.4, which did not differ significantly from 151.3 ± 6.2 in 44 females without the mutation. These findings suggest that the heterozygous missense mutation P561T in the cytoplasmic domain of GHR does not play a significant role in determining the final body height.

Hidesuke Kaji, Third Division, Department of Medicine, Kobe University School of Medicine. 7-5-1. Kusunokicho, Chuo-ku, Kobe 650, Japan







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 European Society of Endocrinology.